Treatment of piles (bawaseer) with Unani medicine Habb-e-Aab-e-Gandana and Marham-e-Bawaseer

Clinical Validation of Habb-e-Aab-e-Gandana and Marham-e-Bawaseer in Bawaseer Amya (Non-bleeding piles) - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/071608

Enrollment

220

Registered

2024-07-30

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K640- First degree hemorrhoids

Interventions

Intervention1: Habb-e-Aab-e-Gandana and Marham-e-Bawaseer: 2 Tablets (500 mg each) to be taken orally twice daily after meals with water and ointment 1gm (as required) to be applied locally twice dail

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients of any sex in the age group 18 to 65 years 2. Patients with a diagnosis of First and Second Degree Hemorrhoids presenting with any of the following symptoms: Mucoid Anal/ Perianal Discharge (Sayal ?n al- Maq‘ad Mukh ?ti): mucus discharge Pruritus Ani (Hikka al-Maq‘ad) Mucosal Prolapse (Khuruj al-Mukh ?tiyya) with Spontaneous Reduction Rectal/ Anal Pain (Waja‘ al-Maq‘ad): on prolapse

Exclusion criteria

Exclusion criteria: 1. Third & Fourth Degree Haemorrhoids, anal fissure, anal fistula, IBD, Diabetes Mellitus 2. Bleeding Per Rectum (Jaray ?n al-Dam fi’l Maq‘ad): bright-red, painless bleeding 3. Known cases of clinically significant co-morbid conditions (severe hepatic, renal, cardiovascular disorders, etc.) 4. Patients with laboratory values outside the normal limits or those with values considered abnormal. 5. Known hypersensitivity to study drug or any of its ingredients 6. History of alcohol and drug abuse 7. Pregnant and Lactating Women

Design outcomes

Primary

Measure	Time frame
The efficacy of the study drug in the treatment of Baw ?sir ?miya (Non-Bleeding Piles) will be assessed on the basis of reduction in the symptoms and signs of the disease. The symptoms will be graded on a Visual Analogue Scale (VAS) of 0 to 100 mm, wherein 0 indicates no symptom and 100 indicates maximum intensity.Timepoint: At baseline, days 7, 14, 28 and 42	—

Secondary

Measure	Time frame
Haematological & biochemical assessment for safety assessment i.e. CBC, LFT, KFT, Urine Routine & microscopic examination.Timepoint: At baseline and after 42days	—

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ghazala.javed@gov.in9811810454

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026